Voyager Therapeutics Shares Outstanding History (VYGR)
Voyager Therapeutics reported 59.0M shares outstanding at the end of fiscal 2025.
View full Voyager Therapeutics company overviewVoyager Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 59.0M | 4.3M | +7.89% |
| 2024 | 2024-12-31 | 54.7M | 10.7M | +24.28% |
| 2023 | 2023-12-31 | 44.0M | 5.4M | +14.05% |
| 2022 | 2022-12-31 | 38.6M | 695,496 | +1.83% |
| 2021 | 2021-12-31 | 37.9M | 550,368 | +1.47% |
| 2020 | 2020-12-31 | 37.4M | 502,911 | +1.36% |
| 2019 | 2019-12-31 | 36.9M | 4.5M | +13.90% |
| 2018 | 2018-12-31 | 32.4M | 792,851 | +2.51% |
| 2017 | 2017-12-31 | 31.6M | 6.0M | +23.34% |
| 2016 | 2016-12-31 | 25.6M | 666,933 | +2.68% |
| 2015 | 2015-12-31 | 24.9M | 24.1M | +2959.64% |
| 2014 | 2014-12-31 | 814,834 | — | — |
Voyager Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 61.3M | 5.8M | +10.53% |
| Q1 2026 | 2026-03-31 | 60.3M | 5.1M | +9.24% |
| Q4 2025 | 2025-12-31 | 59.0M | 4.3M | +7.89% |
| Q3 2025 | 2025-09-30 | 55.5M | 940,214 | +1.72% |
| Q2 2025 | 2025-06-30 | 55.4M | 962,843 | +1.77% |
| Q1 2025 | 2025-03-31 | 55.2M | 891,352 | +1.64% |
| Q4 2024 | 2024-12-31 | 54.7M | 10.7M | +24.28% |
| Q3 2024 | 2024-09-30 | 54.5M | 10.6M | +24.22% |
| Q2 2024 | 2024-06-30 | 54.5M | 10.7M | +24.48% |
| Q1 2024 | 2024-03-31 | 54.3M | 10.9M | +25.05% |
| Q4 2023 | 2023-12-31 | 44.0M | 5.4M | +14.05% |
| Q3 2023 | 2023-09-30 | 43.9M | 5.4M | +13.99% |
| Q2 2023 | 2023-06-30 | 43.8M | 5.3M | +13.84% |
| Q1 2023 | 2023-03-31 | 43.4M | 5.2M | +13.58% |
| Q4 2022 | 2022-12-31 | 38.6M | 695,496 | +1.83% |
| Q3 2022 | 2022-09-30 | 38.5M | 738,550 | +1.95% |
| Q2 2022 | 2022-06-30 | 38.4M | 667,032 | +1.77% |
| Q1 2022 | 2022-03-31 | 38.2M | 685,914 | +1.83% |
| Q4 2021 | 2021-12-31 | 37.9M | 550,368 | +1.47% |
| Q3 2021 | 2021-09-30 | 37.8M | 519,083 | +1.39% |
| Q2 2021 | 2021-06-30 | 37.8M | 568,592 | +1.53% |
| Q1 2021 | 2021-03-31 | 37.6M | 579,304 | +1.57% |
| Q4 2020 | 2020-12-31 | 37.4M | 502,911 | +1.36% |
| Q3 2020 | 2020-09-30 | 37.3M | 434,580 | +1.18% |
| Q2 2020 | 2020-06-30 | 37.2M | 526,019 | +1.43% |
| Q1 2020 | 2020-03-31 | 37.0M | 400,768 | +1.10% |
| Q4 2019 | 2019-12-31 | 36.9M | 4.5M | +13.90% |
| Q3 2019 | 2019-09-30 | 36.8M | 4.5M | +13.98% |
| Q2 2019 | 2019-06-30 | 36.7M | 4.6M | +14.39% |
| Q1 2019 | 2019-03-31 | 36.6M | 4.7M | +14.70% |
| Q4 2018 | 2018-12-31 | 32.4M | 792,851 | +2.51% |
| Q3 2018 | 2018-09-30 | 32.3M | 6.1M | +23.08% |
| Q2 2018 | 2018-06-30 | 32.1M | 6.1M | +23.31% |
| Q1 2018 | 2018-03-31 | 31.9M | 6.0M | +23.35% |
| Q4 2017 | 2017-12-31 | 31.6M | 6.0M | +23.34% |
| Q3 2017 | 2017-09-30 | 26.3M | 831,082 | +3.27% |
| Q2 2017 | 2017-06-30 | 26.0M | 726,615 | +2.87% |
| Q1 2017 | 2017-03-31 | 25.9M | 728,404 | +2.90% |
| Q4 2016 | 2016-12-31 | 25.6M | 666,933 | +2.68% |
| Q3 2016 | 2016-09-30 | 25.4M | 24.0M | +1755.81% |
| Q2 2016 | 2016-06-30 | 25.3M | 24.5M | +3002.01% |
| Q1 2016 | 2016-03-31 | 25.1M | — | — |
| Q4 2015 | 2015-12-31 | 24.9M | — | — |
| Q3 2015 | 2015-09-30 | 1.4M | — | — |
| Q4 2014 | 2014-12-31 | 814,834 | — | — |
Voyager Therapeutics shares outstanding trends
Over the last five reported fiscal years, Voyager Therapeutics's shares outstanding moved from 37.4M to 59.0M, a change of 21.7M. The latest reported quarter, Q2 2026, shows 61.3M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Voyager Therapeutics filings at SEC.gov ↗